Brief: Clinuvel Pharmaceuticals Expects U.S. Shutdown To Impact SEC Review Timelines
03/11/2025 01:34
Nov 3 (Reuters) - Clinuvel Pharmaceuticals Ltd CUV.AX: UPDATE ON ADR UPGRADE, NASDAQ UPLISTING EXPECTS U.S. SHUTDOWN TO IMPACT SEC REVIEW TIMELINES NO FINAL DECISION ON ADR UPLISTING; SUBJECT TO SEC REVIEW PLANS ADR UPGRADE TO LEVEL II ON NASDAQ Further company coverage: CUV.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clinuvel Pharmaceuticals
See all newsBrief: Clinuvel Pharmaceuticals Announces Strategic Reorganisation To Refocus On U.S. Markets
Brief: Clinuvel Pharmaceuticals Ltd's ADS To Commence Trading On Nasdaq
Brief: Clinuvel Pharmaceuticals Says Scenesse Approved For EPP In Canada
Australia's Clinuvel Pharmaceuticals rises on Canada nod for phototoxicity prevention drug
Brief: Clinuvel Pharmaceuticals Updates On Level II ADR Upgrade, Nasdaq Uplist